Epitalon, also known as Epithalon, has been studied in several biological and disease-related models, though the strength of evidence varies significantly depending on the specific condition. Direct research exists in areas including retinal degeneration, reproductive cell ageing, telomere biology and animal ageing, whereas no convincing Epitalon-specific evidence has been identified for fibromyalgia, ALS or clinical use in dogs. [1–5]
Interest in searches regarding Epitalon often extends beyond longevity to include disease-specific topics such as fertility, fibromyalgia, amyotrophic lateral sclerosis (ALS), eye diseases, reproductive aging, and veterinary applications. Such interest is understandable, as Epitalon has been studied in the context of telomere biology, oxidative stress, mitochondrial function, retinal degeneration, gene regulation, and animal aging. However, a biologically plausible mechanism does not mean that every condition associated with oxidative stress, mitochondrial dysfunction, inflammation, or aging has actually been studied using Epitalon. [1]
The evidence also comes from very different levels of research. Some results are based on human cell cultures, others on mouse or bovine reproductive models, a few on ageing or disease experiments in rodents, and only a small number on human clinical trials or ex vivo studies using human material. This distinction is particularly important for disease-specific SEO content, as a mouse oocyte experiment should not be described as a human fertility study, a retinal cell experiment should not be presented as a treatment for diabetic retinopathy, and general neuroprotective mechanisms should not be extended to ALS without direct evidence.
What health conditions are associated with searches regarding Epitalon?
Searches link Epitalon with fertility, fibromyalgia, ALS, retinal diseases, ageing, cancer, cognitive functions and animal health, but these topics do not have equal support in scientific evidence. Retinal degeneration and the ageing of reproductive cells have been the subject of direct experimental research, whereas for fibromyalgia, ALS and clinical use in dogs, comparable, peer-reviewed evidence specific to Epitalon is lacking in the literature analysed here. [1–5]
The broader literature on Epitalon is not focused around one specific disease. Epitalon was originally studied as part of Khavinson's short peptide research programme and subsequently analysed in relation to telomerase, telomere maintenance, chromatin regulation, melatonin, oxidative stress, lifespan and several experimental models concerning specific organs. A 2025 review by Araj and colleagues summarises this diverse evidence base and shows that the compound has been studied primarily using in vitro approaches, animal studies and mechanistic investigations, rather than as part of a single conventional clinical development programme. [1]
However, primary research does exist for a few health conditions. One example is retinal degeneration. A 2002 publication included Campbell rats with inherited retinal degeneration, as well as patients with degenerative retinal changes. The authors reported the preservation of retinal function in the animal model and a positive clinical effect in a number of the patients studied. [2] However, the abstract available on PubMed does not contain sufficient detail to consider these results as conclusive contemporary clinical evidence, because randomisation, blinding, the structure of comparison groups and the full statistical analysis were not adequately described.
Reproductive biology is another area with direct research, although the evidence remains preclinical. A 2022 study analysed post-ovulatory ageing of mouse oocytes in vitro and reported effects on reactive oxygen species, mitochondrial function, spindle abnormalities and apoptosis. [3] A separate 2025 study on cattle analysed oocyte maturation and embryo development after thawing, and reported improvements in endpoints related to telomerase and embryonic development following exposure to Epitalon. [4] Neither of these studies investigated the treatment of human infertility.
Other health-related areas in the broader literature concerning Epitalon include animal tumour models, retinal cell stress models, cognitive ageing experiments in rats, melatonin regulation in monkeys, and telomere research at the cellular level. These results should remain linked to specific experimental models rather than being combined into a general claim that Epitalon „treats age-related diseases”.
Has Epitalon been studied in the context of fertility?
Epitalon has been studied in reproductive biology, but not as an established human infertility treatment. The strongest direct evidence comes from in vitro mouse oocyte studies and a 2025 study on bovine embryo production. These experiments noted effects related to oocyte ageing, mitochondrial function, telomerase-related biology and embryo development, but showed no effect on human pregnancy or fertility. [3,4]
The 2022 study by Yue and colleagues provides the most direct evidence regarding Epitalon in the context of reproductive system ageing. The researchers used mouse oocytes in vitro to analyse post-ovulatory ageing, which is the process whereby oocyte quality gradually deteriorates after ovulation. Epitalon was added to the culture medium at a concentration of 0.1 mM, and the oocytes were evaluated after 6, 12 and 24 hours. [3]
Researchers noted lower levels of intracellular reactive oxygen species, fewer spindle abnormalities and a more normal distribution of cortical granules following exposure to Epitalon. A higher mitochondrial membrane potential and a greater number of mitochondrial DNA copies were also observed, as well as lower apoptosis markers following prolonged in vitro ageing. [3] These results support the potential to influence the quality of ageing mouse oocytes under laboratory conditions.
The study is significant for fertility research because oocyte quality plays a fundamental role in reproduction. However, it does not prove that Epitalon improves fertility in women. The experiment did not assess ovulation, fertilisation rates, implantation, pregnancy, miscarriage, live birth or offspring outcomes in humans. It did not involve administering Epitalon to women or even to whole female mice attempting to get pregnant.
A study published in 2025 in Life Sciences extended this reproductive research to the in vitro production of bovine embryos. Ullah and co-workers analysed telomerase activity during oocyte maturation and embryo cryopreservation. Exposure to Epitalon was associated with improved oocyte maturation, increased post-thaw blastocyst hatching and changes in telomerase, reactive oxygen species, mitochondrial membrane potential and gene expression-related endpoints. [4]
Research on cattle has scientific significance because it analyses oocytes, cumulus cells and embryos within a reproductive biotechnology system. However, the production of bovine embryos is not equivalent to the treatment of human infertility. Interspecies differences, gamete biology, exposure, culture conditions and reproductive physiology make direct clinical extrapolation inappropriate.
The evidence therefore supports a narrow conclusion: Epitalon has been experimentally investigated in the context of germ cell ageing and embryonic development biology in non-human systems. It has not been clinically shown to improve fertility in humans.
Claims that Epitalon „increases female fertility”, „improves IVF success”, „reverses ovarian ageing” or „increases pregnancy rates” require direct human reproductive studies, which are currently lacking in the analysed evidence.
Has Epitalon been researched in the context of fibromyalgia?
Neither in the provided set of studies nor in the targeted searches of peer-reviewed literature conducted for this article was any direct Epitalon-specific study regarding fibromyalgia identified. Although fibromyalgia involves pain, sleep disturbances, fatigue and altered neurobiological signalling, the overlap of these mechanisms does not prove that Epitalon has been studied or shown efficacy in this condition.
Fibromyalgia is a chronic disorder characterised by widespread pain and frequently co-occurring symptoms such as fatigue, sleep disturbances, cognitive difficulties, and increased pain sensitivity. As Epitalon appears in research concerning melatonin, oxidative stress, neuroendocrine regulation, and the biology of ageing, theoretical links can be drawn between some of Epitalon's mechanisms and symptoms associated with fibromyalgia.
This kind of overlap of mechanisms does not constitute sufficient evidence.
For example, Epitalon has been studied in relation to melatonin production in pineal cell systems and in older non-human primates. It has also affected oxidative stress markers in several experimental models. These results do not prove a reduction in generalised pain, improved tender point sensitivity, better physical functioning, or lower symptom assessment scores for fibromyalgia in humans.
A direct study of fibromyalgia would need to include participants with a confirmed diagnosis and evaluate clinically relevant outcomes, such as pain intensity, physical functioning, sleep quality, fatigue, cognitive symptoms, and quality of life. Ideally, such a study should have a randomised, placebo-controlled design.
No study of Epitalon of this type was identified in the evidence analysed here.
Therefore, Epitalon cannot be described as a treatment for fibromyalgia, a pain therapy, or a clinically validated intervention for fibromyalgia solely on the basis of general neuroendocrine or oxidative stress-related mechanisms.
Has Epitalon been investigated in the context of ALS?
No direct peer-reviewed clinical or preclinical study specifically evaluating Epitalon in amyotrophic lateral sclerosis was identified in the evidence analysed for this article. However, Epitalon has neurobiological and oxidative stress studies, including studies on human stem cells and animals, but these results should not be translated into claims regarding the treatment of ALS or motor neuron protection. [1,5]
ALS is a progressive neurodegenerative disease involving the degeneration of upper and lower motor neurons. Its biology encompasses multiple processes, such as protein aggregation, excitotoxicity, mitochondrial dysfunction, RNA processing abnormalities, inflammation and oxidative stress. Because Epitalon has been studied in some of these broader biological areas, particularly in the context of oxidative stress and gene regulation, it may seem superficially relevant.
However, the key point is that biological relevance is not the same as disease-specific evidence.
A 2020 Epitalon study used human gingival mesenchymal stem cells and reported increased expression of neuronal differentiation markers, including Nestin, GAP43, β-tubulin III, and Doublecortin. Molecular modelling in the same study suggested interactions involving histone H1 variants. [5] This provides interesting mechanistic evidence regarding neuronal differentiation pathways in cultured cells.
However, this is not an ALS model.
The cells were not motor neurones obtained from individuals with ALS, the experiment did not model typical genetic abnormalities associated with ALS, and it did not evaluate motor neurone survival, neuromuscular function, disease progression or clinical outcomes.
Epithalon has also been studied in animal and cellular models involving oxidative stress, but oxidative stress occurs in many diseases. A compound that affects reactive oxygen species in one cell type does not automatically become a treatment for every disorder in the pathology of which oxidative stress is involved.
Claims that Epitalon slows the progression of ALS, protects motor neurones, improves muscle function, or extends survival in ALS thus remain unsupported without direct ALS-specific evidence.
Broader neurobiochemical mechanisms are discussed in the article Epitalon Mechanism of Action: How Does the Peptide Work?
Have Epitalon trials been conducted on dogs?
Neither in the supplied evidence base nor in the targeted searches conducted for this article was any peer-reviewed interventional study of Epitalon in dogs identified. Epitalon has been studied in several other animal species, but results obtained in mice, rats, cattle, primates, or in cell cultures cannot substantiate benefits regarding lifespan, healthspan, cognitive function, or disease in dogs.
This distinction is important because animal studies are not automatically dog studies.
Epitalon has an extensive body of literature regarding animal research. The studies have included mice, rats, fruit flies, rhesus macaques, and more recently, bovine reproductive systems. These experiments have evaluated, amongst other things, lifespan, spontaneous tumours, melatonin rhythms, memory, oxidative stress, retinal degeneration, and reproductive cell ageing.
Dogs differ physiologically from each of these experimental models.
The evidence base regarding dogs should ideally encompass species-specific pharmacokinetics, metabolism, exposure, safety, immune responses, organ toxicity, and clinically relevant veterinary outcomes. For ageing-related claims, appropriate endpoints should also include mobility, cognitive function, frailty syndrome, disease incidence, quality of life, healthspan, or survival in appropriately designed canine studies.
No data specific to dogs of this type were identified in the reviewed peer-reviewed literature.
Statements that Epitalon „extends the lives of dogs”, „improves cognitive ageing in dogs”, „reverses ageing in dogs” or „has proven safety in older dogs” should therefore not be presented as established evidence.
The existence of commercial veterinary discussions regarding Epitalon also does not replace peer-reviewed interventional studies in dogs.
Research on mice or rats may provide a scientific rationale for studying a given compound in dogs, but it cannot independently confirm its efficacy or veterinary safety.
What research results on specific diseases actually exist for Epitalon?
There are studies on Epitalon regarding specific diseases, but they focus on a limited number of experimental areas rather than all conditions linked to internet searches. Retinal degeneration has both animal data and limited older human data, reproductive system ageing has data from studies on mice and cattle, and there are additionally several cancer or oxidative stress-related models, whereas many other conditions have not been directly studied. [1–7]
Retinal degeneration is one of the most striking examples of direct research into a specific disease. A study published in 2002 in *Neuro Endocrinology Letters* analysed congenital retinal degeneration in Campbell rats and also presented observations regarding patients with degenerative changes in the retina. [2] According to the abstract in PubMed, Epitalon improved the bioelectrical and functional activity of the retina in an animal model and produced an effect which the authors described as a positive clinical effect in the 90% patients treated.
This result is frequently cited, but requires careful interpretation. The abstract does not contain sufficient methodological information to determine the strength of the clinical evidence according to modern standards. The number of patients, allocation procedures, comparison groups, blinding and endpoint definitions are not adequately described in the abstract. Therefore, this result is better described as an older clinical signal requiring contemporary confirmation, rather than as proof that Epitalon treats retinitis pigmentosa.
A more recent retinal study concerned a different condition and a completely different level of evidence. In 2025, Gatta and co-workers used human retinal pigment epithelium ARPE-19 cells exposed to high glucose concentration as an in vitro model related to diabetic retinopathy. Epitalon improved cell migration and reduced several changes associated with oxidative stress and fibrosis. [6]
This constitutes evidence derived from research on human cells, rather than from the treatment of people with diabetic retinopathy.
Cancer research represents another area related to disease, although results also depend on the specific experimental model. Several older studies in rodents reported a reduction in certain cancer outcomes, whereas at least one bladder carcinogenesis model showed no inhibitory effect of Epitalon. A more recent 2025 study on telomeres in human cells also demonstrated telomere lengthening in breast cancer cell lines via alternative lengthening of telomeres, which highlights why telomere biology cannot be interpreted as unambiguously beneficial. [7]
These examples demonstrate a fundamental principle regarding content about Epitalon and specific medical conditions: the disease, model, species and measured endpoint should remain linked to each specific outcome.
How should preclinical results for specific diseases be interpreted?
Disease-specific preclinical results show that Epitalon influenced a biological process in a given laboratory model; they do not prove that it treats the corresponding disease in humans. Interspecies differences, artificial experimental conditions, exposure levels, disease complexity and pharmacokinetics can mean that promising cellular or animal results may not translate into clinical benefit.
A preclinical experiment answers a narrower question than a clinical trial.
For example, a 2022 study on mouse oocytes shows that Epitalon altered oxidative stress, mitochondrial function, and structural markers in aging mouse oocytes in culture. [3] It does not prove an improvement in fertility in women.
A 2025 study on bovine embryos shows effects during the in vitro production of cattle embryos. [4] It does not prove an improvement in human IVF outcomes.
A 2025 retinal cell study shows that Epitalon affected migration, oxidative stress markers, and fibrosis-related pathways in cultured ARPE-19 cells exposed to high glucose. [6] It does not validate the treatment of diabetic retinopathy.
The same distinction applies to telomere research. Early studies of human fibroblasts showed telomerase activation and telomere elongation, whereas a more recent 2025 study confirmed telomere-related effects in several human cell lines. [7,8] The use of human cells makes these results relevant to human biology, but studies on human cells still differ from clinical trials on humans.
Disease models are deliberately simplified. Researchers can isolate a single pathological process, expose cells to a specific stressor, or use genetically selected animals. Individuals with a disease vary in genetics, disease stage, medications taken, comorbidities and tissue environment, which cannot be fully replicated in laboratory systems.
Therefore, preclinical results can be more accurately described using phrasing such as:
„Epitalon reduced oxidative stress in this model.”
„Epitalon was associated with the improvement of oocyte quality markers in mouse cells.”
„Epitalon altered the response of retinal cells under high glucose conditions.”
They should not be transformed into statements such as:
„Epitalon cures infertility.”
„Epitalon reverses diabetic retinopathy.”
„Epitalon protects against neurological diseases.”
These are clinical claims requiring direct clinical evidence.
Why should a research interest not be presented as clinical efficacy?
Research interest means that a compound has yielded results deemed worthy of further study; clinical efficacy, however, requires evidence that it significantly improves patient health outcomes. The literature on Epitalon contains many biologically interesting results, but most of these stem from cellular studies, animal models, or limited older clinical reports, which is why the overall evidence base does not support broad claims regarding disease treatment. [1]
This distinction is particularly important in the case of Epitalon, as this molecule is linked to several pathways involved in numerous diseases. Telomere shortening is associated with ageing and numerous chronic diseases. Oxidative stress occurs in cardiovascular, neurological, metabolic and inflammatory diseases. Mitochondrial dysfunction is significant in reproduction, neurodegeneration, muscle diseases and ageing. Melatonin and circadian rhythm disorders are linked to sleep disorders and many chronic diseases.
A peptide affecting one of these pathways may therefore appear relevant to many different disorders.
However, a connection to a specific biological pathway does not imply effectiveness in treating every disease in which this pathway is involved.
An example is telomerase. Epitalon increased telomerase activity or telomere length in cultured human cells. [7,8] This demonstrates a cellular effect. It does not prove the prevention of cardiovascular disease, neurodegeneration, infertility, fibromyalgia, or general ageing.
The same applies to oxidative stress. Epitalon reduced the levels of reactive oxygen species in mouse oocytes and retinal cell models. [3,6] These results do not confirm that systemic administration produces an equivalent antioxidant effect in patients with diseases unrelated to these models.
Clinical efficacy typically requires controlled human trials utilising patient-relevant outcomes. Depending on the condition, appropriate outcomes may include pregnancy and live birth rates for fertility, pain and physical functioning in fibromyalgia, disease progression and survival in ALS, visual function in retinal diseases, or quality of life and survival in the case of ageing animals.
Without such data, the scientifically correct stance is not to state that Epitalon „does not work” in every unstudied condition. The correct stance is to state that its efficacy has not been established.
What clinical evidence in humans exists for individual health conditions?
Clinical evidence regarding Epitalon in humans is considerably narrower than the preclinical literature. The most prominent publication concerning a specific condition is an older report on retinitis pigmentosa, whilst much of the remaining human-related evidence comes from cultured human cells, ex vivo tissues, or limited neuroendocrine observations rather than contemporary randomised clinical trials concerning specific diseases. [1,2,7,8]
The publication regarding the retina is relevant because PubMed classifies it as a clinical trial, and its abstract clearly describes the treatment of patients with degenerative retinal changes. [2] However, the reporting of the methodology is incomplete by modern standards, and therefore this study should not be interpreted as definitive proof of efficacy.
Other frequently cited „human studies” on Epitalon are actually laboratory experiments using material of human origin.
The classic 2003 study by Khavinson, Bondarev and Butyugov involved the exposure of human foetal fibroblasts to Epithalon and demonstrated the induction of the catalytic component of telomerase, telomerase activity and telomere elongation. [8]
The 2025 study by Al-Dulaimi used normal human fibroblast and mammary epithelial cell lines along with two human breast cancer cell lines. The researchers observed telomere elongation via different mechanisms depending on the cell type. [7] These are human cells, but Epitalon was not administered to any person.
Ex vivo studies using human material also included cultured lymphocytes obtained from older people and demonstrated an effect on chromatin organisation. Studies of this type can help in elucidating possible mechanisms, but do not prove the treatment of a disease.
Articles discussing Epitalon in relation to a specific health condition should therefore distinguish whether the compound was actually studied in patients with that condition.
When it comes to fertility, fibromyalgia, ALS and dogs, the answer based on the evidence analysed here is: no.
Evidence by condition at a glance
| Medical condition or area of research | The best identified evidence regarding Epitalon | What can reasonably be stated? |
|---|---|---|
| Human fertility | No direct clinical trial was identified | No benefit to human fertility has been established. |
| Oocyte ageing | Mouse oocytes in vitro [3] | Epitalon affected oxidative stress, mitochondria, and oocyte quality markers in mouse cells. |
| Embryonic development | In vitro production of bovine embryos [4] | An improvement in bovine oocyte/embryo endpoints was noted; this does not constitute evidence regarding human IVF. |
| Fibromyalgia | No direct study has been identified | It is not possible to formulate an evidence-based claim of efficacy. |
| MND | No direct ALS study was identified | General neurobiological results cannot be extrapolated to ALS. |
| Psy | No peer-reviewed intervention study in dogs was identified | Efficacy in dogs, impact on lifespan, and safety remain unestablished. |
| Retinitis pigmentosa | Rat model + older human clinical report [2] | A clinical signal has been reported, but contemporary controlled confirmation is lacking. |
| Biology of diabetic retinopathy | Human retinal cell line under high glucose conditions [6] | Significant cellular effects were noted; this was not a clinical trial of the treatment. |
| Telomere shortening | Human cell cultures [7,8] | Epitalon can affect telomere maintenance mechanisms in vitro. |
| Cancers | Numerous animal/cellular models with mixed results | No claim regarding the treatment or prevention of cancer in humans has been established. |
| Overall longevity | Animal models | No extension of human life has been demonstrated. |
Frequently asked questions about Epitalon and health conditions
Is Epitalon used in the context of fertility?
Epitalon has been studied in mouse oocytes and bovine embryo production systems, where researchers have noted effects related to oxidative stress, mitochondrial function, telomerase-related biology and developmental endpoints. [3,4] No controlled human fertility study has demonstrated an improvement in fertilisation rates, IVF success, implantation, pregnancy or live birth rates.
Can Epitalon improve egg cell quality?
A 2022 in vitro study of mouse oocytes reported an improvement in structural and mitochondrial markers in post-ovulatorily aged oocytes following exposure to Epitalon. [3] This supports a preclinical effect on markers of mouse oocyte quality, but does not prove that Epitalon improves human egg quality or fertility.
Has Epitalon been researched in the context of fibromyalgia?
No direct study of Epitalon regarding fibromyalgia was identified in the evidence analysed for this article. Research involving melatonin, oxidative stress and neuroendocrine biology does not support pain reduction or clinical efficacy in fibromyalgia.
Has Epitalon been investigated in the context of ALS?
No direct peer-reviewed studies regarding ALS have been identified. Epitalon has neurobiological and gene regulation studies using cultured cells, but these experiments were not ALS models and do not demonstrate motor neurone protection or the slowing of ALS progression in humans. [5]
Has Epitalon been used in dogs?
There are commercial discussions on this topic, but no peer-reviewed interventional study in dogs was identified in the literature analysed here. Results obtained in mice, rats, cattle or non-human primates cannot substantiate canine life extension, healthspan improvement, veterinary dosage or long-term safety.
Has Epitalon been studied in humans?
Yes, although evidence concerning humans remains limited. An older clinical publication included patients with retinal degeneration, while other human-related studies utilised cultured fibroblasts, epithelial cells or lymphocytes ex vivo. [2,7,8] These different types of evidence should not be considered equivalent.
Does Epitalon treat retinitis pigmentosa?
An older 2002 publication reported positive effects in Campbell rats and patients with retinal degeneration. [2] The result is of clinical interest, but the publication does not provide the detailed, contemporary evidence from randomised trials needed for Epitalon to be recognised as a treatment for retinitis pigmentosa.
Does Epitalon have proven efficacy in age-related diseases?
No. Epitalon has been studied in numerous age-related biological processes and disease models, but there is no widespread clinical evidence showing that it treats age-related diseases as a category. Each condition requires its own controlled clinical evidence.
Limitations of evidence regarding Epitalon in individual diseases
The greatest limitation is the varying degree of directness of the evidence. The scope of searches is much broader than the experimental literature. Epitalon is searched in connection with fertility, fibromyalgia, ALS, cancer, retinal diseases and animal ageing, but only some of these topics have direct research on Epitalon.
Another limitation is the frequent equating of human cells with human clinical evidence. A fibroblast or retinal epithelial cell may be of human origin, but exposing these cells to AEDG in culture is fundamentally different from administering the peptide to a patient and measuring disease outcomes.
Thirdly, the evidence regarding reproduction remains non-human. A 2022 study on mouse oocytes and a 2025 study on bovine embryos are valuable mechanistic and assisted reproductive technology experiments, but neither supports claims regarding human fertilisation, ovarian reserve, IVF success, or pregnancy. [3,4]
Fourthly, older human clinical reports require careful interpretation. The publication concerning retinitis pigmentosa provides an important human signal, but its abstract does not describe many of the methodological features expected of contemporary clinical studies. [2]
Fifthly, the lack of evidence must also be described precisely. Failing to identify a study regarding fibromyalgia, ALS or dogs does not prove that Epitalon could never exert an effect in these contexts. It means that the clinical efficacy currently remains unestablished.
Finally, Epitalon's activity across multiple biological pathways particularly facilitates over-extrapolation. Telomerase, oxidative stress, mitochondria, gene regulation and melatonin are involved in many disorders, but the overlap of pathways provides a rationale for further research rather than proof of treatment efficacy.
Conclusions
Epitalon has been studied in several health-related contexts, but the available evidence does not support presenting it as a general treatment for age-related or chronic diseases. The strongest research regarding specific conditions includes an older study on retinal degeneration, the cellular ageing of mouse reproductive cells, studies on bovine embryo development, and several disease-relevant cell or animal models. [2–6]
Regarding fertility, the evidence remains preclinical and is limited to mouse oocytes and bovine reproductive systems. Regarding fibromyalgia, no direct studies specific to Epitalon were identified. Regarding ALS, no direct evidence specific to this disease was identified despite broader neurobiological research. Regarding dogs, no peer-reviewed interventional studies involving this species were identified in the reviewed literature.
A scientifically valid interpretation should therefore be specific to each condition: every result must be linked to the precise research model, cellular and animal data should be kept separate from clinical evidence in humans, and mechanistic significance should not be transformed into claims regarding clinical efficacy.
Disclaimer
The article is of an exclusively educational and scientific-informative nature and does not constitute medical advice, diagnosis, treatment guidelines, veterinary advice or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental compound in the health contexts discussed here. Preclinical results concerning mouse oocytes, bovine embryos, retinal cells or other experimental systems should not be interpreted as proof of efficacy in humans or animals. Evidence regarding humans remains limited, and clinical efficacy has not been established for fibromyalgia, ALS, human fertility or longevity in dogs.
References
[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691.
https://doi.org/10.3390/ijms26062691
[2] Khavinson, V., Razumovsky, M., Trofimova, S., Grigorian, R., & Razumovskaya, A. (2002). Pineal-regulating tetrapeptide Epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters, 23(4), 365–368.
https://pubmed.ncbi.nlm.nih.gov/12195242/
[3] Yue, X., Liu, S.-L., Guo, J.-N., Meng, T.-G., Zhang, X.-R., Li, H.-X., Song, C.-Y., Wang, Z.-B., Schatten, H., Sun, Q.-Y., & Guo, X.-P. (2022). Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Ageing, 14(7), 3191–3202.
https://doi.org/10.18632/aging.204007
[4] Ullah, S., Haider, Z., Perera, C. D., Lee, S. H., Idrees, M., Park, S., & Kong, I.-K. (2025). Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. Life Sciences, 362, 123381.
https://doi.org/10.1016/j.lfs.2025.123381
[5] Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., & Sinjari, B. (2020). AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: Possible epigenetic mechanism. Molecules, 25(3), 609.
https://doi.org/10.3390/molecules25030609
[6] Gatta, M., Dovizio, M., Milillo, C., Ruggieri, A. G., Sallese, M., Antonucci, I., Trofimov, A., Khavinson, V., Trofimova, S., Bruno, A., & Ballerini, P. (2025). The antioxidant tetrapeptide Epitalon enhances delayed wound healing in an in vitro model of diabetic retinopathy. Stem Cell Reviews and Reports, 21(6), 1822–1834.
https://doi.org/10.1007/s12015-025-10911-x
[7] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178.
https://doi.org/10.1007/s10522-025-10315-x
[8] Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592.
https://doi.org/10.1023/A:1025493705728